Drugs / IDOV-SAFETM
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06713148 | Apr → Dec 2025 overdue | cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06346041 | Apr 2024 → Dec 2025 overdue | neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDOV-SAFETM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06713148 ↗ |
| Modality | Other / unclassified | “Oncolytic Virus injection(IDOV-SAFETM)” NCT06346041 ↗ |
| Route | Intravenous | “Administered by intravenous injection as single agent.” NCT06346041 ↗ |